Myozyme (Alglucosidase alfa)

Myozyme (alglucosidase alfa) is a lysosomal glycogen-specific enzyme indicated for use in patients with Pompe disease (GAA deficiency). This therapeutic drug has been shown to improve ventilator-free survival in patients with infantile-onset Pompe disease as compared to an untreated historical control, whereas use of this drug in patients with other forms of Pompe disease has not been adequately studied to assure safety and efficacy.

Recommended Dosage:
The recommended dosage regimen of Alglucosidase alfa is 20 mg/kg body weight administered every 2 weeks as an intravenous (IV) infusion.

• Serious allergic reactions, including anaphylaxis, may occur during or after infusion. Signs and symptoms include swelling, difficulty breathing, rashes, or chest pain. Always monitor patients throughout infusion and have emergency treatment ready. Stop treatment quickly if a serious allergic response occurs.
• Certain patients might experience responses that attack the immune system’s cells. These responses may lead to inflammation of organs such as the skin or kidneys. If any symptoms that you consider unusual arise, please see your physician without delay. It is highly advisable to check the immune response to treatment from time to time.
• Alglucosidase alfa can be responsible for causing breathing or heart complications during infusion, particularly in those with underlying heart or lung disease. Monitor closely throughout and after infusion. Use caution and consider pre-treatment testing for high-risk individuals to reduce complications.
• Common infusion-related reactions include nausea, fever, chills, headache, and low blood pressure. These usually arise during or shortly after administration. Slowing the infusion rate or giving pre-medicine may help reduce the signs and symptoms. Stop infusion if serious reactions occur and provide proper supportive care.
• Regular lab tests must be performed to check kidney function, liver enzymes, and immune response. Monitoring helps detect early side effects or allergic reactions. Blood tests before and after treatment ensure safety and allow timely dose adjustments when necessary.
• There is limited information on the use of Alglucosidase alfa during pregnancy. It should only be used if the potential benefit justifies the risk to the unborn baby. Pregnant women must consult their healthcare provider (HCP) before starting or continuing treatment.
• It is not known if this therapeutic drug passes into human breast milk. A breastfeeding mother should discuss with her clinician about the risks and benefits. Based on the child’s health and the mother’s requirement for treatment, breastfeeding may need to be paused.

What documents are required to import MYOZYME to India?

MYOZYME (alglucosidase alfa) injections can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is MYOZYME available in India?

MYOZYME (alglucosidase alfa injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On availability of Myozyme in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

MYOZYME can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of MYOZYME (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Myozyme 5 mg/mL injection price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source MYOZYME (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

What is the Generic Name for the trade name drug Myozyme®?

What is the Manufacturer's Name of Myozyme®?

Is Myozyme® approved by the FDA?

What is the dosage and form of Myozyme® supplied?

What are the most common side effects of Myozyme® 5 mg/mL injection? 

How much does Myozyme® 5 mg/mL injection cost in India?

Can Myozyme® 5 mg/mL injections be available in SAARC countries? 

Is it safe to buy Myozyme® 5 mg/mL injection online in India?

What are the storage conditions of Myozyme® 5 mg/mL injections?